|
CLL leukemic cells
|
0.5 nM
|
MTT assay
|
Download PDF
|
|
KG1A cells
|
136 nM (single agent), 40.9 nM (combination)
|
Luminescent Assay
|
Download PDF
|
|
M07e cells
|
1045 nM (single agent), 132 nM (combination)
|
Luminescent Assay
|
Download PDF
|
|
MOLM-14
|
10.5 nM (venetoclax alone), 7.7 nM (venetoclax + DMF 50 µM)
|
WST-1 cell proliferation assay
|
Download PDF
|
|
venetoclax-resistant MOLM-14
|
85.8 nM (venetoclax + DMF 100 µM)
|
WST-1 cell proliferation assay
|
Download PDF
|
|
SU-DHL-8 (DLBCL cell line)
|
5.943 uM
|
Cell viability determined using CCK8 assay
|
Download PDF
|
|
OCI-Ly10 (DLBCL cell line)
|
5049 nM
|
Cell viability determined using CCK8 assay
|
Download PDF
|
|
HMC3 (normal microglial cells)
|
100 µM
|
Dose-dependent inhibition of viability assay
|
Download PDF
|
|
ONS76 (medulloblastoma cell line)
|
10 µM
|
Dose-dependent inhibition of viability assay
|
Download PDF
|
|
DAOY (medulloblastoma cell line)
|
0.1 µM
|
Dose-dependent inhibition of viability assay
|
Download PDF
|
|
HDMB03 (medulloblastoma cell line)
|
100 µM
|
Dose-dependent inhibition of viability assay
|
Download PDF
|
|
RIVA (DLBCL cell line)
|
~0.1 µM
|
Cell viability assay
|
Download PDF
|
|
U2932 (DLBCL cell line)
|
~0.1 µM
|
Cell viability assay
|
Download PDF
|
|
SUDHL8 (DLBCL cell line)
|
>100 µM
|
Cell viability assay
|
Download PDF
|
|
SUDHL10 (DLBCL cell line)
|
>100 µM
|
Cell viability assay
|
Download PDF
|
|
U2932 R1 subclone (DLBCL cell line)
|
>100 µM
|
Cell viability assay
|
Download PDF
|
|
U2932 R2 subclone (DLBCL cell line)
|
<0.0001 µM
|
Cell viability assay
|
Download PDF
|
|
U2932 R2 subclone (DLBCL cell line) in co-culture with hCD40L-3T3
|
~1 µM
|
Cell viability assay
|
Download PDF
|
|
RIVA (DLBCL cell line) in co-culture with hCD40L-3T3
|
~1 µM
|
Cell viability assay
|
Download PDF
|
|
U2932 (DLBCL cell line) in co-culture with hCD40L-3T3
|
~0.1 µM
|
Cell viability assay
|
Download PDF
|
|
MOLM-13 (venetoclax-resistant)
|
>10000 nmol/L (resistant)
|
Luminescent Cell Viability Assay
|
PMC12260509
|
|
AML cells (UAMOCS1 subtype)
|
1.438 µM
|
Cell viability assay
|
Download PDF
|
|
AML cells (UAMOCS2 subtype)
|
3.145 µM
|
Cell viability assay
|
Download PDF
|
|
AML cells (UAMOCS3 subtype)
|
3.188 µM
|
Cell viability assay
|
Download PDF
|
|
LAPC4-AI organoids
|
~10 µM
|
Resazurin cell viability assays
|
PMC12265624
|
|
ALL leukemic cells (CD19+ B-cells)
|
1.5 nM
|
MTT assay
|
Download PDF
|
|
OCI-LY19 (SETD1Bwt)
|
~5 nM
|
Luminescent assay
|
PMC11380151
|
|
OCI-LY19 (SETD1B deficient)
|
~2 µM
|
Luminescent assay
|
PMC11380151
|
|
OCI-LY8 (SETD1Bwt)
|
~136 nM
|
Luminescent assay
|
PMC11380151
|
|
OCI-LY8 (SETD1B deficient)
|
~1.2 µM
|
Luminescent assay
|
PMC11380151
|
|
SU-DHL-10 (SETD1Bwt)
|
~100 nM
|
Luminescent assay
|
PMC11380151
|
|
SU-DHL-10 (SETD1B deficient)
|
~1.5 µM
|
Luminescent assay
|
PMC11380151
|
|
OCI-LY8 (KMT2D deficient)
|
~22 nM
|
Luminescent assay
|
PMC11380151
|
|
HL-60/ADR cells
|
9.47µM (24h), 6.11µM (48h)
|
Cell Counting Kit-8 (CCK-8) assay
|
PMC11674180
|
|
NB4 (human promyelocytic leukemia cell line)
|
1.2 µM
|
MTS assay
|
Download PDF
|
|
CL1 (NB4 APL cell line)
|
3.2 µM
|
MTS assay
|
Download PDF
|
|
CL1-R (NB4 APL cell line)
|
0.3 µM
|
MTS assay
|
Download PDF
|
|
CL2 (NB4 APL cell line)
|
6.4 µM
|
MTS assay
|
Download PDF
|
|
CL2-R (NB4 APL cell line)
|
0.04 µM
|
MTS assay
|
Download PDF
|
|
CL3 (NB4 APL cell line)
|
4.5 µM
|
MTS assay
|
Download PDF
|
|
CL3-R (NB4 APL cell line)
|
3.3 µM
|
MTS assay
|
Download PDF
|
|
CL4 (NB4 APL cell line)
|
3.9 µM
|
MTS assay
|
Download PDF
|
|
CL4-R (NB4 APL cell line)
|
3.9 µM
|
MTS assay
|
Download PDF
|
|
KMS-12PE
|
10.22 nM
|
Luminescent Cell Viability Assay
|
PMC11339023
|
|
KMS-27
|
37.04 nM
|
Luminescent Cell Viability Assay
|
PMC11339023
|
|
U937 (human AML cell line)
|
0.12 µM
|
MTT assay
|
PMC10911724
|
|
KG-1 (human AML cell line)
|
0.18 µM
|
MTT assay
|
PMC10911724
|
|
OSU-CLL
|
0.005 ± 0.001 μM
|
MTS assay (mitochondrial activity)
|
Download PDF
|
|
VR-OSUCLL
|
10.0 ± 0.0 μM
|
MTS assay (mitochondrial activity)
|
Download PDF
|
|
PDX-expanded blasts (BMP-high)
|
11 nM
|
Imaging-based assay with a stromal cell coculture system, dose-response curves generated
|
PMC11779640
|
|
PDX-expanded blasts (BMP-low)
|
2000 nM
|
Imaging-based assay with a stromal cell coculture system, dose-response curves generated
|
PMC11779640
|
|
KG-1A
|
250 nM
|
Apoptosis evaluation by flow cytometry (Annexin V and 7-AAD staining) and ZIP model for synergy calculation.
|
PMC10680489
|
|
THP-1
|
950 nM
|
Apoptosis evaluation by flow cytometry (Annexin V and 7-AAD staining) and ZIP model for synergy calculation.
|
PMC10680489
|
|
Mono-AML cell lines; Prim-AML cell lines
|
1,901 nmol/L (Mono-AML); 12 nmol/L (Prim-AML)
|
Cell viability assessed using Luminescent Cell Viability Assay.
|
PMC10236156
|
|
AML patient samples (BeatAML dataset)
|
≤ 1 μM (sensitive), ≥ 10 μM (resistant)
|
Definition of sensitive/resistant groups based on IC50 thresholds from existing drug response data
|
Download PDF
|
|
AML patient samples (Tavor dataset)
|
≤ 1 μM (sensitive), ≥ 10 μM (resistant)
|
Definition of sensitive/resistant groups based on IC50 thresholds from existing drug response data
|
Download PDF
|
|
MOLM13 (Venetoclax sensitive)
|
0.005 μM
|
(CTG) assay
|
Download PDF
|
|
MOLM13 (Venetoclax resistant)
|
34.86 μM
|
(CTG) assay
|
Download PDF
|
|
CLL cells
|
1,000-fold shift
|
Viability measured using DiOC6 and TO-PRO-3, specific apoptosis calculated.
|
PMC10772535
|
|
CII
|
~50 nM
|
Cell viability measured by Cell Titer Blue assay (colorimetric cell-based assay) combined with multi-well plate spectral analysis.
|
Download PDF
|
|
MEC-1
|
~75 nM
|
Cell viability measured by Cell Titer Blue assay (colorimetric cell-based assay) combined with multi-well plate spectral analysis.
|
Download PDF
|
|
Eµ-Myc/dCas9a-SAMKI/+/sgBcl-2 lymphoma-derived cell lines
|
0.11 µM
|
Cell viability determined by propidium iodide (PI) staining followed by flow cytometric analysis.
|
Download PDF
|
|
Eµ-Myc lymphoma-derived cell lines
|
> 1 µM
|
Cell viability determined by propidium iodide (PI) staining followed by flow cytometric analysis.
|
Download PDF
|
|
CLL-CII cells
|
0.37 µM
|
MTT assay, calculated with Prism 6.01 software
|
PMC9468723
|
|
CLL-CII cells
|
0.24 µM
|
MTT assay, calculated with Prism 6.01 software
|
PMC9468723
|
|
SU-DHL2 (human DLBCL cell line)
|
0.245 µM
|
Cell Counting Kit-8 (CCK-8) assay
|
Download PDF
|
|
OCI-LY1 (human DLBCL cell line)
|
2.824 µM
|
Cell Counting Kit-8 (CCK-8) assay
|
Download PDF
|
|
TMD8 (human DLBCL cell line)
|
>10 µM
|
Cell Counting Kit-8 (CCK-8) assay
|
Download PDF
|
|
SU-DHL4 (human DLBCL cell line)
|
>10 µM
|
Cell Counting Kit-8 (CCK-8) assay
|
Download PDF
|
|
SU-DHL6 (human DLBCL cell line)
|
1.192 µM
|
Cell Counting Kit-8 (CCK-8) assay
|
Download PDF
|
|
SU-DHL10 (human DLBCL cell line)
|
>10 µM
|
Cell Counting Kit-8 (CCK-8) assay
|
Download PDF
|
|
SU-DHL16 (human DLBCL cell line)
|
0.164 µM
|
Cell Counting Kit-8 (CCK-8) assay
|
Download PDF
|
|
CLL cells (in BCA medium)
|
0.042 μM
|
Cell viability assay (annexin V/PI and flow cytometry)
|
Download PDF
|
|
CLL samples (#57, #77)
|
>10 μM
|
Cell viability assay (annexin V/PI and flow cytometry)
|
Download PDF
|
|
MV4-11 (human AML cell line)
|
0.00016 μM
|
MTT assay
|
Download PDF
|
|
Panc-1 (human pancreas cancer cell line)
|
0.99 μM
|
MTT assay
|
Download PDF
|
|
A549 (human lung cancer cell line)
|
0.99 μM
|
MTT assay
|
Download PDF
|
|
MUTZ5 (human Ph-like ALL cell line)
|
0.785 µmol/L
|
Cell-Titer Glo viability assays, GraphPad Prism, Compusyn software
|
PMC8448976
|
|
MHH-cALL-4 (human Ph-like ALL cell line)
|
0.285 µmol/L
|
Cell-Titer Glo viability assays, GraphPad Prism, Compusyn software
|
PMC8448976
|
|
TVA-1 (human ABL-class Ph-like ALL cell line)
|
2.2 nmol/L
|
Cell-Titer Glo viability assays, GraphPad Prism, Compusyn software
|
PMC8448976
|
|
KG-1 (human acute myeloid leukemia cell line)
|
0.223 µM (24h), 0.140 µM (48h)
|
CCK8 assay
|
Download PDF
|
|
Kasumi-1 (human acute myeloid leukemia cell line)
|
0.197 µM (24h), 0.097 µM (48h)
|
CCK8 assay
|
Download PDF
|
|
THP-1 (human acute myeloid leukemia cell line)
|
0.174 µM (24h), 0.153 µM (48h)
|
CCK8 assay
|
Download PDF
|
|
MV4-11 (AML cell line)
|
12.54 ± 2.69 nM (24h), 9.07 ± 1.30 nM (48h)
|
Cell Counting Kit-8 (CCK8) assay
|
Download PDF
|
|
MOLM13 (AML cell line)
|
9.81 ± 1.13 nM (24h), 2.86 ± 1.51 nM (48h)
|
Cell Counting Kit-8 (CCK8) assay
|
Download PDF
|
|
OCL-AML2 (AML cell line)
|
126.2 ± 2.43 nM (24h), 15.67 ± 0.65 nM (48h)
|
Cell Counting Kit-8 (CCK8) assay
|
Download PDF
|
|
OCL-AML3 (AML cell line)
|
34.1 ± 0.49 nM (24h), 3.87 ± 0.69 nM (48h)
|
Cell Counting Kit-8 (CCK8) assay
|
Download PDF
|
|
MOLM-13
|
0.0085 µM
|
XTT assay
|
Download PDF
|
|
U937
|
0.663 µM
|
XTT assay
|
Download PDF
|
|
OCI-AML3
|
1.115 µM
|
XTT assay
|
Download PDF
|
|
MCF-7 (human breast cancer cell line)
|
36 ± 5.3 μM
|
Muse® Count & Viability assay
|
Download PDF
|
|
SKBR-3 (human breast cancer cell line)
|
34 ± 7.1 μM
|
Muse® Count & Viability assay
|
Download PDF
|
|
MDA-MB-231 (human breast cancer cell line)
|
60 ± 4.2 μM
|
Muse® Count & Viability assay
|
Download PDF
|
|
SMS-SAN
|
5 nM
|
WST-1 assay
|
Download PDF
|
|
NB-1643
|
1.5 nM
|
WST-1 assay
|
Download PDF
|
|
IMR5
|
>500 nM
|
WST-1 assay
|
Download PDF
|
|
Toledo (Diffuse Large B-Cell Lymphoma cell line)
|
~100 nM
|
luminescent cell viability assay
|
Download PDF
|
|
SU-DHL-4 (Diffuse Large B-Cell Lymphoma cell line)
|
~10 nM
|
luminescent cell viability assay
|
Download PDF
|
|
SU-DHL-6 (Diffuse Large B-Cell Lymphoma cell line)
|
~10 nM
|
luminescent cell viability assay
|
Download PDF
|
|
OCI-LY1 (Diffuse Large B-Cell Lymphoma cell line)
|
~10 nM
|
luminescent cell viability assay
|
Download PDF
|
|
OCI-LY3 (Diffuse Large B-Cell Lymphoma cell line)
|
~100 nM
|
luminescent cell viability assay
|
Download PDF
|
|
OCI-LY7 (Diffuse Large B-Cell Lymphoma cell line)
|
~10 nM
|
luminescent cell viability assay
|
Download PDF
|
|
OCI-LY8 (Diffuse Large B-Cell Lymphoma cell line)
|
~10 nM
|
luminescent cell viability assay
|
Download PDF
|
|
OCI-LY10 (Diffuse Large B-Cell Lymphoma cell line)
|
~10 nM
|
luminescent cell viability assay
|
Download PDF
|
|
U2932 (Diffuse Large B-Cell Lymphoma cell line)
|
~100 nM
|
luminescent cell viability assay
|
Download PDF
|
|
WSU-DLCL2 (Diffuse Large B-Cell Lymphoma cell line)
|
~100 nM
|
luminescent cell viability assay
|
Download PDF
|
|
HT (Diffuse Large B-Cell Lymphoma cell line)
|
>10 µM
|
luminescent cell viability assay
|
Download PDF
|
|
Jeko-1 (Mantle Cell Lymphoma cell line)
|
~10 nM
|
luminescent cell viability assay
|
Download PDF
|
|
Mino (Mantle Cell Lymphoma cell line)
|
~10 nM
|
luminescent cell viability assay
|
Download PDF
|
|
Rec-1 (Mantle Cell Lymphoma cell line)
|
~10 nM
|
luminescent cell viability assay
|
Download PDF
|
|
Granta-519 (Mantle Cell Lymphoma cell line)
|
~100 nM
|
luminescent cell viability assay
|
Download PDF
|
|
Z-138 (Mantle Cell Lymphoma cell line)
|
>10 µM
|
luminescent cell viability assay
|
Download PDF
|
|
Raji (Burkitt Lymphoma cell line)
|
>10 µM
|
luminescent cell viability assay
|
Download PDF
|
|
Ramos (Burkitt Lymphoma cell line)
|
>10 µM
|
luminescent cell viability assay
|
Download PDF
|
|
Daudi (Burkitt Lymphoma cell line)
|
>10 µM
|
luminescent cell viability assay
|
Download PDF
|
|
CA46 (Burkitt Lymphoma cell line)
|
>10 µM
|
luminescent cell viability assay
|
Download PDF
|
|
BL-41 (Burkitt Lymphoma cell line)
|
>10 µM
|
luminescent cell viability assay
|
Download PDF
|
|
SU-DHL-4 (co-culture with immune cells and HUVEC)
|
14 nm
|
Cell proliferation assay
|
Download PDF
|
|
SU-DHL-8 (co-culture with immune cells and HUVEC)
|
32 nm
|
Cell proliferation assay
|
Download PDF
|
|
CLL cells
|
2.5 nM
|
Apoptosis quantified by measuring phosphatidylserine externalisation
|
Download PDF
|
|
Ri-1 WT DLBCL cells
|
0.02 µM
|
Cell death measurement using flow cytometry of Annexin V-FITC/7-AAD stained cells. LD50 values were determined.
|
Download PDF
|
|
Ri-1 VR DLBCL cells
|
0.31 µM
|
Cell death measurement using flow cytometry of Annexin V-FITC/7-AAD stained cells. LD50 values were determined.
|
Download PDF
|
|
LAPC4-AI organoids
|
10 μM
|
Cell viability measured by Resazurin
|
PMC13134962
|
|
MV4-11 (human AML cell line)
|
Relative IC50: 18 nM (single agent), 8 nM (combination); Abs
|
CellTiter-Glo® assay (viability) and Annexin-V-Fluos staining (apoptosis)
|
Download PDF
|
|
MOLM-13 (human AML cell line)
|
Relative IC50: 20 nM (single agent), 7 nM (combination); Abs
|
CellTiter-Glo® assay (viability) and Annexin-V-Fluos staining (apoptosis)
|
Download PDF
|
|
OCI-AML-3 (human AML cell line)
|
Relative IC50: -- (single agent), 142 nM (combination); Abso
|
CellTiter-Glo® assay (viability) and Annexin-V-Fluos staining (apoptosis)
|
Download PDF
|
|
HL-60 (human promyelocytic cell line)
|
Relative IC50: 4 nM (single agent); Absolute IC50: 4 nM (sin
|
CellTiter-Glo® assay (viability) and Annexin-V-Fluos staining (apoptosis)
|
Download PDF
|